Effects of hemodialysis with cooled dialysate on high-sensitivity cardiac troponin I and brain natriuretic peptide

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.

The aim of the study was to compare HD with cooled dialysate with routine dialysis in terms of hemodynamic stability and levels of high-sensitivity Troponin I (hs-TnI) and N-terminal pro b-type natriuretic peptide (NTproBNP) pre and postdialysis.

Why It Was Studied

Hemodialysis (HD) triggers recurrent and cumulative ischemic insults to the brain and the heart.

Who Took Part

The abstract describes 45 patients taking part.

The 45 patients were randomized into two groups.

Then groups crossed over, so each group received the alternate dialysate (self-controls) For each patient, the first sample was collected at the beginning of dialysis, and a second sample was taken at the end of dialysis.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.

The first group received a 35.5°C dialysate first (hypothermic dialysis) and the second group a 36.5°C dialysate first (routine dialysis).

What Was Measured

The subject headings attached to it are Blood Pressure, Dialysis Solutions, Natriuretic Peptide, Brain, Renal Dialysis and Troponin I.

The authors tagged it with the keywords cardiovascular, hemodialysis delivery systems and outcomes research.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide) in 45 patients.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Hemodialysis international. International Symposium on Home Hemodialysis), a journal based in Canada.

More context: the BNP (Nesiritide) compound page, all human trials.